JHS Svendgaard Laboratories Limited
Incorporated in 1997, JHS Svendgaard Laboratories Ltd does manufacturing oforal and dental products for national and international brands
What JHS files
- Others68
- Important10
- Board Meeting10
- Updates8
- Results3
JHS Svendgaard's board approved reallocating 29.99 Cr from its preferential issue. Funds shift from specific equipment/group infusion to broader Capital Expenditure & Business Expansion (11.75 Cr) and Strategic & Growth Initiatives (10.75 Cr), alongside General Corporate (7.50 Cr), for enhanced flexibility.
Company's committee granted 2,50,000 Employee Stock Options, convertible into equity shares. The exercise price is fixed at Rs. 10 per option. This move aligns employee incentives, potentially leading to future share dilution upon exercise.
JHS Svendgaard allotted ~18 lakh new shares at Rs 27.75 each to Coeus Global Opportunities Fund via warrant conversion. This brought in ₹3.75 Cr, increasing paid-up capital to ₹87.41 Cr. Positive capital infusion.
JHS Svendgaard received a warning from NSE & BSE due to the Stakeholders Relationship Committee Chairperson's absence at the AGM. The company expects no financial impact and is implementing corrective measures to ensure future compliance.
JHS Svendgaard Laboratories' AGM approved an Employee Stock Option Scheme – 2025. This allows for up to 0.4 Cr new equity shares to be issued to employees, potentially diluting existing shareholders. No grants made yet.